Neurotensin active 2,3,diaryl-pyrazolidine derivatives
The invention relates to a group of novel 2,3 diaryl-pyparazolidine derivatives having formula (1). The symbols used in formula (1) have the meanings given in the specification. The compounds have inhibiting activity on enzymes which degrade the neuropeptide neurotensin and can be used for the treatment of affections and diseases caused by disturbances of the neurotensin mediated transmission.
1. A compound of the formula (1)
wherein,
S 1 is chosen from hydrogen, halogen, hydroxy and alkoxy (1–3C);
S 2 is chosen from hydrogen and halogen;
S 3 is chosen from hydrogen, halogen, hydroxy and alkoxy (1–3C);
S 4 is chosen from hydrogen, halogen and alkyl (1–6C) optionally substituted with hydroxy, alkoxy (1–3C), amino, mono- or dialkylamino having 1–3C-atoms in the alkyl group(s), SH or S-alkyl (1–3C);
X is chosen from nitrogen and carbon;
Y is chosen from nitrogen and oxygen when X is nitrogen, or Y is nitrogen when X is carbon;
R 3 and R 4 , which may be identical or different, are chosen from hydrogen and alkyl (1–3C);
R 5 is chosen from hydrogen and alkyl (1–6C) which may be substituted with halogen, CN, CF 3 , hydroxy, alkoxy (1–3C), sulfonylalkyl (1–3C), amino, mono- or dialkylamino having 1–3C-atoms in the alkyl group(s) when X is carbon or nitrogen, or R 5 represents alkoxy (1–6C), SH or S-alkyl (1–3C) when X is carbon;
R′ 5 is chosen from hydrogen and alkyl (1–3C);
R 6 is chosen from hydrogen, and alkyl (1–3C);
R 7 is chosen from hydrogen and alkyl (1–3C); or
R 5 and R 6 together or R′ 5 and R 6 together can form a 3–7 membered cyclic group which is optionally substituted with a group chosen from lower alkyl, halogen, CN and CF 3 , and R 5 +R′ 5 together optionally form a 3–7 membered ring;
Z 1 , Z 2 and Z 3 are chosen from carbon, or Z 1 is nitrogen and Z 2 and Z 3 are carbon, or Z 1 and Z 3 are carbon and Z 2 is nitrogen, or Z 1 and Z 2 are carbon and Z 3 is nitrogen;
A is chosen from a (poly) cycloalkyl system comprising 4–10 membered rings which are optionally substituted with a group chosen from halogen, CF 3 , alkyl or alkoxy (1–3C), CN, OH and SH;
and pharmacologically acceptable salts thereof.
2. A process for the preparation of a compound as claimed in claim 1 , wherein the compound is prepared according to one of the following:
A)
wherein after step i two diastereomers evolve which, after step iii has been performed, can be seperated by column chromatography into enantiomeric pure diastereomers using a Chiralcel CD column (25×5 cm 2 , 20μ, eluent; hexane/ethanol 4/1)into enantiomeric pure diastereomers;
B)
wherein the reaction steps i and ii are identical with those in scheme A;
C)
D)
wherein the reaction steps i and ii are identical with the steps iii and iv in scheme C.
3. A pharmaceutical composition comprising at least one compound as claimed in claim 1 as an active ingredient.
4. A method of treating at least one disorder involving neurotensin mediated transmission in a patient in need thereof, comprising administering to the patient at least one compound as claimed in claim 1 in an amount effective for treating the disorder, wherein the at least one disorder is chosen from psychosis, Parkinson's disease, depression and anxiety disorders.